[Effectiveness and safety of rituximab in pemphigus vulgaris].
Alonso Sánchez
A
A
García Rodríguez
S
S
López Avila
A
A
Rabell Iñigo
S
S
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D002990:Clobetasol / Q000008:administration & dosage / Q000627:therapeutic use; D057176:Compassionate Use Trials; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D010392:Pemphigus / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab
D000890:Anti-Infective Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab; D002990:Clobetasol; D009173:Mycophenolic Acid; D001379:Azathioprine; D011241:Prednisone
Eficacia y seguridad de rituximab en pénfigo vulgar.